TY - JOUR
T1 - Extracellular vesicles as a drug delivery system
T2 - A systematic review of preclinical studies
AU - Escudé Martinez de Castilla, Pol
AU - Tong, Lingjun
AU - Huang, Chenyuan
AU - Sofias, Alexandros Marios
AU - Pastorin, Giorgia
AU - Chen, Xiaoyuan
AU - Storm, Gert
AU - Schiffelers, Raymond M.
AU - Wang, Jiong-Wei
N1 - Funding Information:
The authors would like to thank the funding support from the Singapore Ministry of Health’s National Medical Research Council (NMRC/OFYIRG/0081/2018 to J.W.W., G.P. and G.S.), NUHS (NUHSRO/2018/095/RO5 + 5/Seed-Nov/05 to J.W.W.; NUHSRO/2021/034/TRP/09/Nanomedicine to X.C., G.S., and J.W.W.), NUS ODPRT Cross-Faculty Research Fund (CFGFY20P14 to J.W.W.), the National University of Singapore NanoNASH Program (NUHSRO/2020/002/NanoNash/LOA to G.S., G.P., and J.W.W.), the National University of Singapore start-up fund (NUHSRO/2020/133/Startup/08 to X.C.; NUHSRO/2019/077/STARTUP/03-ODPRT and NUHSRO/2019/077/STARTUP/03-NUSMed to G.S.), the National University of Singapore (R-148-000-296-114 and R-148-000-284-114 to G.P.) and the RIE2020 Advanced Manufacturing and Engineering (AME) Industry Alignment Fund – Pre Positioning (IAF-PP) grant (A20G1a0046 and R-148-000-307-305 to G.P.), and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (proEVLifeCycle, grant No 860303; and the B-SMART project, grant No 721058; to R.M.S). Figs. 1, 2, 14–16 were created with BioRender.com.
Funding Information:
The authors would like to thank the funding support from the Singapore Ministry of Health's National Medical Research Council (NMRC/OFYIRG/0081/2018 to J.W.W. G.P. and G.S.), NUHS (NUHSRO/2018/095/RO5?+?5/Seed-Nov/05 to J.W.W.; NUHSRO/2021/034/TRP/09/Nanomedicine to X.C. G.S. and J.W.W.), NUS ODPRT Cross-Faculty Research Fund (CFGFY20P14 to J.W.W.), the National University of Singapore NanoNASH Program (NUHSRO/2020/002/NanoNash/LOA to G.S. G.P. and J.W.W.), the National University of Singapore start-up fund (NUHSRO/2020/133/Startup/08 to X.C.; NUHSRO/2019/077/STARTUP/03-ODPRT and NUHSRO/2019/077/STARTUP/03-NUSMed to G.S.), the National University of Singapore (R-148-000-296-114 and R-148-000-284-114 to G.P.) and the RIE2020 Advanced Manufacturing and Engineering (AME) Industry Alignment Fund ? Pre Positioning (IAF-PP) grant (A20G1a0046 and R-148-000-307-305 to G.P.), and the European Union's Horizon 2020 research and innovation programme under the Marie Sk?odowska-Curie grant agreement (proEVLifeCycle, grant No 860303; and the B-SMART project, grant No 721058; to R.M.S). Figs. 1, 2, 14?16 were created with BioRender.com.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/8
Y1 - 2021/8
N2 - During the past decades, extracellular vesicles (EVs) have emerged as an attractive drug delivery system. Here, we assess their pre-clinical applications, in the form of a systematic review. For each study published in the past decade, disease models, animal species, EV donor cell types, active pharmaceutical ingredients (APIs), EV surface modifications, API loading methods, EV size and charge, estimation of EV purity, presence of biodistribution studies and administration routes were quantitatively analyzed in a defined and reproducible way. We have interpreted the trends we observe over the past decade, to define the niches where to apply EVs for drug delivery in the future and to provide a basis for regulatory guidelines.
AB - During the past decades, extracellular vesicles (EVs) have emerged as an attractive drug delivery system. Here, we assess their pre-clinical applications, in the form of a systematic review. For each study published in the past decade, disease models, animal species, EV donor cell types, active pharmaceutical ingredients (APIs), EV surface modifications, API loading methods, EV size and charge, estimation of EV purity, presence of biodistribution studies and administration routes were quantitatively analyzed in a defined and reproducible way. We have interpreted the trends we observe over the past decade, to define the niches where to apply EVs for drug delivery in the future and to provide a basis for regulatory guidelines.
KW - 2022 OA procedure
KW - Drug delivery
KW - Extracellular vesicles
KW - Liposomes
KW - Preclinical animal models
KW - Systematic review
KW - Clinical trial
UR - http://www.scopus.com/inward/record.url?scp=85109583131&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2021.05.011
DO - 10.1016/j.addr.2021.05.011
M3 - Review article
C2 - 34015418
AN - SCOPUS:85109583131
SN - 0169-409X
VL - 175
JO - Advanced drug delivery reviews
JF - Advanced drug delivery reviews
M1 - 113801
ER -